Mouse models for immuno-oncology

Marcus Bosenberg; Edison T Liu; Chun I Yu; Karolina Palucka

doi:10.1016/j.trecan.2023.03.009

Mouse models for immuno-oncology

Trends Cancer. 2023 Jul;9(7):578-590. doi: 10.1016/j.trecan.2023.03.009. Epub 2023 Apr 20.

Authors

Marcus Bosenberg¹, Edison T Liu², Chun I Yu³, Karolina Palucka⁴

Affiliations

¹ Department of Dermatology, Yale School of Medicine, New Haven, CT, USA. Electronic address: marcus.bosenberg@yale.edu.
² The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; The Jackson Laboratory Cancer Center, Bar Harbor, ME, USA. Electronic address: ed.liu@jax.org.
³ The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; The Jackson Laboratory Cancer Center, Bar Harbor, ME, USA.
⁴ The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; The Jackson Laboratory Cancer Center, Bar Harbor, ME, USA. Electronic address: karolina.palucka@jax.org.

PMID: 37087398
DOI: 10.1016/j.trecan.2023.03.009

Abstract

Realizing the clinical promise of cancer immunotherapy is hindered by gaps in our knowledge of in vivo mechanisms underlying treatment response as well as treatment limiting toxicity. Preclinical in vivo model systems and technologies are required to address these knowledge gaps and to surmount the challenges faced in the clinical application of immunotherapy. Mice are commonly used for basic and translational research to support development and testing of immune interventions, including for cancer. Here, we discuss the advantages and the limitations of current models as well as future developments.

Keywords: cancer immunotherapy; collaborative cross mice; diversity outbred mice; genetically engineered mice; humanized mice; mouse model.

Publication types

Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Disease Models, Animal
Immunotherapy
Medical Oncology
Mice
Neoplasms* / drug therapy
Translational Research, Biomedical

Abstract

Publication types

MeSH terms

Grants and funding